Lyvgen is a biotech company focused on developing novel therapies for cancer. Our world-leading cross-linking antibody (xLinkAb™) functional platform creates new biology and molecules with tumor-localized immunostimulatory activities. Our most advanced clinical candidates LVGN6051 (CD137/4-1BB agonist) and LVGN7409 (CD40 agonist) differentiate themselves from competition by their selective FcγRIIB binding and natural IgG structure. Our xLinkAb synthetic biology further enables innovation on bispecific antibodies (xLinkBsAb) and multispecific antibodies (xLinkMsAb) to address global unmet medical needs. Lyvgen innovation lives in our people, our laboratories, and our clinical trials.
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.